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Objective: It has been reported that a failed endovascular intervention adversely affects results of lower extremity
bypass (LEB). We reviewed rates of prior endovascular intervention (PEI) in patients undergoing LEB with autol-
ogous vein for critical limb ischemia (CLI) to determine effects on graft patency, limb salvage, and amputation-free
survival.
Methods: Retrospective review was conducted of consecutive autologous vein LEBs performed for CLI between 2005 and
2012 at a tertiary care academic medical center.
Results: Overall, 314 autologous vein LEBs were performed for CLI, 71% for tissue loss. TransAtlantic Inter-Society
Consensus II type D or type C lesions were present in 62% and 25%, respectively. The great saphenous vein was
used as a conduit in 83%, and the distal target was infrapopliteal in 60%. The 30-day mortality rate was 3.5%. Primary
patency rates at 1 year and 5 years were 61% and 45%. Secondary patency rates at 1 year and 5 years were 88% and 64%,
with 23% requiring an intervention to maintain patency. The 5-year limb salvage rate was 89%, and the 5-year
amputation-free survival was 49%. There were 61 patients (19%) who had undergone a PEI and 253 (81%) who un-
derwent bypass with no prior endovascular intervention (NPEI). There were 19 iliac stents, 29 femoral interventions,
13 popliteal interventions, 9 crural interventions, 9 infrainguinal thrombectomies, and 13 infrainguinal thrombolyses.
PEI and NPEI patients had similar demographics and prevalence of atherosclerotic risk factors. The 1-year primary
patency rate was 62% for NPEI patients vs 59% for PEI patients (P [ .759). The 1-year and 2-year secondary patency
rates were 87% and 79% for NPEI patients vs 89% and 78% for PEI patients (P [ .947). The 3-year limb salvage rate
was 89% for NPEI patients vs 92% for PEI patients (P [ .445). The 3-year amputation-free survival was 59% for NPEI
patients vs 52% for PEI patients (P [ .399). Median follow-up time was 323 days for NPEI patients (interquartile
range, 83-918) vs 463 days for PEI patients (interquartile range, 145-946; P [ .275).
Conclusions: Overall operative mortality, patency rates, and limb salvage for autologous vein LEB in CLI patients
continue to be excellent in the endovascular era and are not necessarily affected by a prior ipsilateral endovascular pro-
cedure. Long-term survival remains poor in CLI patients requiring LEB. (J Vasc Surg 2014;60:129-35.)Catheter-based interventions have expanded treatment
options for patients with critical limb ischemia (CLI).
When endovascular procedures fail in a patient with CLI,
the alternative is frequently autogenous vein lower extrem-
ity bypass (LEB). In fact, the inevitable correlate of
increased use of primary endovascular intervention is that
LEBs will, of necessity, have to be performed in patients
who have had prior failed endovascular interventions.1-4
Previous reports have raised concerns about the potentialthe Department of Surgerya and Division of Vascular Surgery,b
regon Health and Science University.
or conﬂict of interest: none.
ented at the Twenty-eighth Annual Meeting of the Western Vascular
ciety, Jasper, Alberta, Canada, September 21-24, 2013.
rint requests: Vincent J. Santo, MD, Division of Vascular Surgery,
regon Health and Science University, 3181 SW Sam Jackson Park
d, Portland, OR 97239 (e-mail: santo@ohsu.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery. Published by
sevier Inc. All rights reserved.
://dx.doi.org/10.1016/j.jvs.2014.01.013negative impact of failed endovascular procedures on sub-
sequent LEB outcomes.5-10
It is possible, however, that a failed endovascular inter-
vention is not necessarily associated with worse outcomes
for LEB among CLI patients in all practice settings. The pur-
pose of this study was to review the experience at our institu-
tion to determine if prior ipsilateral endovascular intervention
was associated with impaired patency, limb salvage, or
amputation-free survival in patients undergoing LEB forCLI.METHODS
From a prospectively maintained vascular surgical regis-
try, we constructed a database that included all patients who
underwent LEB with autologous vein for CLI between
2005 and 2012. The time period selected for the study cor-
responded to the implementation of an electronic medical
record system at Oregon Health and Science University
and increasing use of catheter-based procedures in our prac-
tice. The study was approved by the Oregon Health and
ScienceUniversity Institutional Review Board and informed
consent waived as this was an analysis of registry data.
Electronic medical records were retrospectively rev-
iewed for each case to extract the following prespeciﬁed129
Table I. Prior endovascular interventions (PEIs)
No. (%)
Pelvic stent 19 (31.1)
Femoral stent 8 (13.1)
Femoral angioplasty 14 (23.0)
Femoral atherectomy 7 (11.4)
Popliteal stent 5 (8.2)
Popliteal angioplasty 5 (8.2)
Popliteal atherectomy 3 (4.9)
Crural stent 1 (1.6)
Crural angioplasty 5 (8.2)
Crural atherectomy 3 (4.9)
Infrainguinal thrombectomy 9 (14.8)
Infrainguinal thrombolysis 13 (21.3)
There were 92 PEIs performed in 61 patients.
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cation use, physical examination ﬁndings, prior lower
extremity interventions, operative indication, results of pre-
operative vein mapping, operative procedure, morbidity
and mortality, preoperative and postoperative angiographic
results, reinterventions, and patterns of graft failure. Pri-
mary, primary assisted, and secondary patency as well as
limb salvage, amputation-free survival, and overall survival
were calculated by Kaplan-Meier methods.
Comorbidities were considered present when docu-
mented in chart notes. Medication use was that at the
time of initial consultation for LEB for CLI. Renal insuf-
ﬁciency was deﬁned as a serum creatinine concentration
>1.4 mg/dL before operation. Patients were catego-
rized as former smokers if they had quit >8 weeks before
operation. Preoperative vein mapping was performed by
an Intersocietal Accreditation Commissioneaccredited
vascular laboratory, and measurements were taken from
ofﬁcial diagnostic reports. Postoperative wound compli-
cations were deﬁned according to the Szilagyi criteria.11
Major amputations were deﬁned as those at the transti-
bial or transfemoral level. Toe or partial foot amputa-
tions were classiﬁed as minor amputations. Graft
patency was deﬁned according to established Society
for Vascular Surgery standards.12 Our bypass graft sur-
veillance protocol included duplex scans every 3 months
for 1 year and, depending on ﬁndings and interventions,
continued short-interval scanning or once yearly at min-
imum. Loss to follow-up was deﬁned as 18 months
without clinic visit or correspondence. Mortality was
determined from chart records and the Social Security
Death Index.
Categorical variables were analyzed by c2 or Fisher
exact test. Continuous variables were analyzed by unpaired
Student t-test or Mann-Whitney test. Normally distributed
variables are expressed as means 6 standard deviation;
nonparametric variables are expressed as medians (inter-
quartile range). Time-to-event variables were analyzed by
log-rank test of Kaplan-Meier analysis.
Analyses were performed with SPSS version 21 statisti-
cal software (IBM Corp, Armonk, NY). Signiﬁcance was
set at P ¼ .05 in all cases, and two-sided values were
reported where applicable.
RESULTS
Between 2005 and 2012, there were 383 consecutive,
autologous vein LEBs performed in 332 patients at our
institution. All bypasses were performed with use of reverse
vein. There were 314 LEBs performed for CLI, which make
up the study population; 71% (222) were performed for tis-
sue loss. Of the CLI patients, 63% were men. TransAtlantic
Inter-Society Consensus II (TASC) type D or type C lesions
were present in 191 (61%) and 79 (25%), respectively. The
great saphenous vein was used as the conduit in 260 oper-
ations (83%), and the distal target was an infrapopliteal
artery in 188 (60%). The 30-day mortality rate was 3.5%.
To maintain patency, 72 grafts (23%) underwent a reinter-
vention. The 1-year and 5-year primary patency rates were61% and 45%. The 1-year and 5-year secondary patency
rates were 88% and 64%. The 5-year limb salvage rate was
89%, and the 5-year amputation-free survival was 49%.
There were 61 patients (19%) who had undergone 92
prior endovascular interventions (PEIs); 253 patients
(81%) had not undergone a prior endovascular intervention
(NPEI). These prior interventions are detailed in Table I.
The indications for these PEIs were unknown in 8 (13%),
CLI in 42 (69%), and intermittent claudication in 11
(18%). At the time of bypass, 27 patients (44%) had inter-
ventions that were still patent.
Additional demographics are presented in Table II.
The PEI group had a decreased prevalence of hyperten-
sion and an increased prevalence of clopidogrel use,
despite similar overall antiplatelet use. The two groups
were similar in other respects. Median follow-up time
was 323 days for the NPEI group (interquartile range,
83-918) vs 463 days for the PEI group (interquartile
range, 145-946; P ¼ .275).
Tissue loss was present in 181 NPEI patients (71.5%)
and 41 PEI patients (67.2%; P ¼ .505). In the NPEI
group with tissue loss, 107 wounds (59%) were in the
forefoot, 30 (17%) in the hindfoot, and 27 (15%) in the
lower leg. In the PEI group, 24 wounds (59%) were in
the forefoot, 5 (12%) in the hindfoot, and 8 (20%) in
the lower leg. These differences were not statistically
signiﬁcant. TASC II classiﬁcations are presented in
Table III, showing a trend toward more severe occlusions
in the NPEI group.
The distribution of proximal and distal anastomotic
sites was not different between groups (Table IV). The
great saphenous vein was used in 215 NPEI bypasses
(85%) and 45 PEI bypasses (74%) (P ¼ .005). This differ-
ence was accompanied by a roughly equivalent increase in
the use of arm vein in the PEI group compared with the
NPEI group, 16 (26%) vs 34 (14%), respectively
(P ¼ .005). A venovenostomy was required in 35 NPEI
bypasses (14%) and 12 PEI bypasses (20%) (P ¼ .251). The
minimum vein diameter was 3.3 6 0.9 mm in the
NPEI group vs 2.96 0.8 mm in the PEI group (P ¼ .009).
Endoscopic vein harvest was used in 90 NPEI bypasses
Table II. Baseline patient characteristics and
comorbidities






Age,b years 67.2 6 12.5 66.9 6 12.7 .883
BMI,c kg/m2 26.7 (23-32.2) 25.9 (23.6-30.0) .280
HTN 208 (82.2) 40 (65.6) .004
HLD 113 (44.7) 23 (37.7) .325
DM .578
None 125 (49.4) 28 (45.9)
NIDDM 59 (23.3) 18 (29.5)
IDDM 69 (27.3) 15 (24.6)
CAD 109 (43.1) 27 (44.3) .867
Prior CVA 48 (19.0) 9 (14.8) .443
CKD 60 (23.7) 11 (18.0) .341
Creatinine,b
mg/dL
1.5 6 1.3 1.5 6 1.6 .871
Dialysis 28 (11.1) 7 (11.5) .928
COPD 33 (13.0) 4 (6.6) .158
Tobacco use .445
None 52 (20.6) 17 (27.9)
Prior 103 (40.7) 25 (41.0)
Current 98 (38.7) 19 (31.1)
Normal pulses
Femoral 168 (69.8) 43 (75.4) .642
Popliteal 27 (11.1) 8 (14.0) .619
Pedal 2 (0.8) 0 (0) .121
Antiplatelet 162 (64.0) 45 (73.8) .150
Aspirin 145 (57.3) 38 (62.3) .479
Clopidogrel 40 (15.8) 20 (32.8) .002
Dipyridamole 4 (1.6) 1 (1.6) 1.000
Beta-blocker 130 (51.4) 33 (54.1) .703
Statin 117 (46.2) 30 (49.2) .680
Anticoagulation 41 (16.2) 9 (14.8) .781
BMI, Body mass index; CAD, coronary artery disease; CKD, chronic kidney
disease (serum creatinine concentration >1.5); COPD, chronic obstructive
pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus;
HLD, hyperlipidemia; HTN, hypertension; IDDM, insulin-dependent dia-
betes mellitus; NIDDM, noninsulin-dependent diabetes mellitus; NPEI, no
prior endovascular intervention; PEI, prior endovascular intervention.
aCategorical variables are presented as number (%), c2 analysis.
bMean 6 standard deviation, unpaired Student t-test, two-tailed analysis.
cMedian (interquartile range), Mann-Whitney analysis.
Table III. Preoperative lesion characteristics:
TransAtlantic Inter-Society Consensus (TASC) II
NPEI (n ¼ 253) PEI (n ¼ 61) P value
TASC II classiﬁcation .127
Unknown 27 (10.8) 7 (11.7)
B 4 (1.6) 3 (5.0)
C 59 (23.5) 20 (33.3)
D 163 (64.4) 31 (50.8)
NPEI, No prior endovascular intervention; PEI, prior endovascular
intervention.
Data are presented as number (%), c2 analysis.
Table IV. Arterial inﬂow and outﬂow
NPEI (n ¼ 253) PEI (n ¼ 61) P value
Inﬂow vessel
External iliac 4 (1.6) 1 (1.6) 1.000
Common femoral 100 (39.5) 23 (37.7) .794
Profunda femoris 39 (15.4) 9 (14.8) .898
Superﬁcial femoral 63 (24.9) 18 (29.5) .460
Above-knee popliteal 8 (3.2) 2 (3.3) 1.000
Below-knee popliteal 23 (9.1) 6 (9.8) .857
Aortofemoral graft 3 (1.2) 1 (1.6) .580
Iliofemoral graft 2 (0.8) 1 (1.6) .478
Popliteal graft 2 (0.8) 0 (0) 1.000
Axillary-femoral graft 4 (1.6) 0 (0) 1.000
Femoral-femoral graft 5 (2.0) 0 (0) .587
Outﬂow vessel
Above-knee popliteal 25 (9.9) 5 (8.2) .688
Below-knee popliteal 73 (28.9) 23 (37.7) .178
Tibioperoneal trunk 4 (1.6) 1 (1.6) 1.000
Posterior tibial 53 (20.9) 12 (19.7) .825
Anterior tibial 39 (15.4) 8 (13.1) .651
Peroneal 47 (18.6) 8 (13.1) .314
Pedal 12 (4.8) 4 (6.6) .289
NPEI, No prior endovascular intervention; PEI, prior endovascular
intervention.





(n ¼ 61) P value
Mortality (30-day) 10 (4.0) 1 (1.6) .698
Length of hospital staya 10 (6-14.75) 9 (6-14) .771
Myocardial infarction
(30-day)
13 (5.3) 3 (5.0) 1.000
Pneumonia (30-day) 4 (1.6) 1 (1.7) 1.000
Urinary tract infection
(30-day)
6 (2.5) 1 (1.7) 1.000
Cerebrovascular accident
(30-day)
3 (1.2) 2 (3.3) .258
Any wound complication 100 (39.5) 30 (49.2) .169
NPEI, No prior endovascular intervention; PEI, prior endovascular
intervention.
Data are presented as number (%), c2 analysis, unless otherwise indicated.
aMedian (interquartile range), Mann-Whitney analysis.
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times were 296 6 96 minutes in the NPEI group vs 282 6
96 minutes in the PEI group (P ¼ .324).
Perioperative morbidity and mortality are presented in
Table V. There was no difference between groups. Szilagyigrade I wound complications occurred in 61% of the
NPEI group vs 53% of the PEI group (P ¼ .253). Szilagyi
grade II occurred in 35% of the NPEI group vs 18% of the
PEI group (P ¼ .628). Szilagyi grade III occurred in 4%
of the NPEI group vs 13% of the PEI group (P ¼ .008).
Primary LEB patency at 1 year was 61.5% for NPEI
patients vs 58.8% for PEI patients (P ¼ .759) (Fig 1). Sec-
ondary patency at 1 year and 2 years was 87.1% and 79.2%
for NPEI patients vs 89.4% and 78.2% for PEI patients
(P ¼ .947) (Fig 2).
There were 76 minor amputations (30.6%) in the
NPEI group and 18 (30%) in the PEI group (P ¼ .624).
There were 26 major amputations (10.5%) in the NPEI
group and 4 (6.7%) in the PEI group (P ¼ .588). Limb
salvage at 3 years was 88.9% in the NPEI group vs 91.7%
in the PEI group (P ¼ .445) (Fig 3). Amputation-free
Fig 1. Primary patency for no prior endovascular intervention
(NPEI) vs prior endovascular intervention (PEI); number at risk is
shown above the x-axis. P value ¼ Kaplan-Meier log-rank test.
Fig 2. Secondary patency for no prior endovascular intervention
(NPEI) vs prior endovascular intervention (PEI); number at risk is
shown above the x-axis. P value ¼ Kaplan-Meier log-rank test.
Fig 3. Limb salvage for no prior endovascular intervention
(NPEI) vs prior endovascular intervention (PEI); number at risk is
shown above the x-axis. P value ¼ Kaplan-Meier log-rank test.
Fig 4. Amputation-free survival for no prior endovascular inter-
vention (NPEI) vs prior endovascular intervention (PEI); num-
ber at risk is shown above the x-axis. P value ¼ Kaplan-Meier
log-rank test.
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in the PEI group (P ¼ .399; Fig 4). Overall survival was
65.3% in the NPEI group vs 56.5% in the PEI group
(P ¼ .160; Fig 5).
In the NPEI group, 55 grafts (21.7%) required an inter-
vention to maintain or to restore patency during the study
period, compared with 18 grafts (29.5%) in the PEI group
(P ¼ .236). The median time to intervention was 190.5
(IQR, 82.8-285.5) days for NPEI vs 131 (IQR, 64-197.8)
days for PEI (P ¼ .178). Of these 55 NPEI grafts, 31
(56.4%) ultimately required operative intervention compared
with 13 of 18 revised PEI grafts (72.2%; P ¼ .277).
Because some would argue that the inclusion of iliac
stents biases the outcomes of the PEI group, we performed
the same analysis excluding the 16 patients whose mostdistal intervention was an iliac stent. The primary demo-
graphic results reported before were essentially unchanged.
There was an increased prevalence of hypertension diag-
nosed in the NPEI group. The NPEI group was more
likely to have a bypass with saphenous vein, and those veins
were larger on average. Otherwise, there were no signiﬁ-
cant differences between groups. The 1-year primary
patency was 61% for NPEI patients vs 56% for PEI patients
(P ¼ .580). The 2-year secondary patency was 78% for
NPEI patients vs 74% for PEI patients (P ¼ .740). Limb
salvage was 91% for both NPEI and PEI groups at 2 years.
Amputation-free survival was 59% for NPEI patients vs 52%
for PEI patients at 3 years (P ¼ .466). Overall survival was
65% vs 59% at 3 years (P ¼ .346).
Fig 5. Overall survival for no prior endovascular intervention
(NPEI) vs prior endovascular intervention (PEI); number at risk is
shown above the x-axis. P value ¼ Kaplan-Meier log-rank test.
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The goal of our study was to determine whether PEI
was associated with inferior outcomes for LEB performed
for CLI. With respect to patency, graft-directed reinterven-
tion, limb salvage, amputation-free survival, and survival,
we could ﬁnd no statistical differences in our patients
who underwent LEB for CLI before or after a catheter-
based intervention for lower extremity ischemia.
There are no randomized trials directly addressing
the effect of previous catheter-based interventions on
subsequent LEB for CLI. Results of the Bypass vs Angio-
plasty in Severe Ischaemia of the Leg (BASIL) trial most
closely approximate a randomized trial to address the ef-
fects of catheter interventions on subsequent LEB for
CLI. Aiming to compare an endovascular-ﬁrst with a
bypass-ﬁrst approach for CLI, the trial randomized 452
patients to percutaneous transluminal angioplasty (PTA)
or autologous vein LEB; 37 patients randomized to
PTA had early failures and ultimately required LEB.
Compared with those who had a primary bypass per-
formed after randomization, these 37 suffered inferior
amputation-free survival rates.13
Consistent with the analysis of the BASIL trial, a num-
ber of other investigators have also found inferior results
for LEB after endovascular interventions. Most other
studies are, however, also quite small. Bockler et al14
reported worsening clinical ischemia and inferior patency
rates in a series of 18 patients who received a bypass after
failed infrainguinal stenting compared with a selected
comparison group of contemporary primary bypasses. In
2008, Joels et al15 reported on early failures in 23 of
276 patients undergoing endovascular interventions of
the superﬁcial femoral artery. Of those, 28% had a change
in ideal distal anastomotic site as judged by blind review
of preintervention and postintervention angiograms by
three vascular surgeons. Although statistically insigniﬁcant,
a trend was noted toward inferior patency, limb salvage,and runoff quality in those patients who had alteration of
the distal anastomotic site. CLI patients were also more
likely to have alteration of their ideal distal anastomotic
site compared with intermittent claudication patients
(42% vs 11%).
In the largest series of which we are aware, there was a
roughly 50% increased risk in graft occlusion or amputation
among 132 bypasses performed after endovascular inter-
vention compared with 1277 bypasses performed in the
absence of prior endovascular revascularization.16 Howev-
er, this series from the Vascular Study Group of New
England reﬂects regional results from many hospitals and
does not necessarily reﬂect what can or will be achieved
in all practice settings.
There are also prior studies arguing against a negative
impact of PEIs on LEB. All are retrospective series. Parsons
et al6 reported a series of 307 PTAs in 257 CLI patients; 59
went on to LEB. The 1-year patency of these LEBs was
more than 70%, which compares favorably with our results
and previously published data.17-19 Ryer et al7 described
251 patients (42% with CLI) treated with primary PTA
with or without stenting. Five ultimately required bypass,
and they claim that the ability to perform the bypass was
not affected; however, no long-term outcomes were re-
ported. Dosluoglu et al5 compared outcomes for a large se-
ries analyzing an endovascular-ﬁrst vs bypass-ﬁrst approach
to CLI patients. They had 22 endovascular-ﬁrst patients
who ultimately required a bypass. In this group, three
required amputation for an amputation rate of 14%, which
was equivalent to the amputation rate of the overall group.
They concluded that bypass after endovascular intervention
is a rare event and is not adversely affected by endovascular
intervention. These studies are joined by others suggesting
minimal impact of failed endovascular intervention on LEB
and infrequent impact on distal anastomotic sites, although
the numbers are small.8-10
A strength of our study was that apart from the PEI
group’s having an increased baseline prevalence of clopi-
dogrel use, group demographics were otherwise well
matched. There was a similar prevalence of tissue loss and
the level at which it was present between groups. Operative
conduct was also well matched, with similar proximal and
distal anastomotic sites in both groups. Ultimately, our
patency rates were comparable to prior randomized data,
such as those provided in the PREVENT III trial.17 The
1-year primary patency rate for our cohort was identical
to that reported in the trial, 61%. The 1-year secondary
patency rate was 80% in PREVENT III, whereas our over-
all secondary patency rate at 1 year was 88%.
Factors that were not well matched and could have
confounded comparisons between groups included venous
conduit characteristics and preoperative disease burden.
The PEI group more frequently required arm vein as a
conduit, and minimum vein diameter on preoperative
vein mapping was 0.4 mm smaller. In our patients, these
differences would have been expected to lead to worse out-
comes in the PEI group. Conversely, the NPEI group
appeared to have more severe atherosclerotic burden at
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toward increased prevalence of TASC type D lesions.
We acknowledge that our study was not a prospective
randomized trial. This allows a number of inherent biases,
most apparent being patient selection. However, there are
also no prior studies designed or randomized to speciﬁcally
determine whether an endovascular intervention negatively
affects subsequent LEB, thus subjecting them to potentially
the same biases. Our study argues that with appropriate pa-
tient selection, results of LEB are not necessarily impaired
by PEI. Endovascular intervention should not be avoided
solely for concerns about the effect on subsequent LEB
bypass should the endovascular intervention fail. However,
achieving these results is likely to require very careful preop-
erative planning, including angiography and vein mapping;
experience with alternative vein conduits and composite
vein conduits; and willingness to perform revisions for graft
defects identiﬁed with postoperative graft surveillance.
The category of “prior endovascular interventions”
captures a heterogeneous population. We included patients
with prior iliac stenting in our primary analysis to capture
all patients who received prior endovascular treatment,
whereas other studies speciﬁcally excluded suprainguinal
interventions. A separate analysis excluding iliac stents did
not change our primary results.
Itwas not possible to knowprocedural details of thePEIs
in all patients as many of these interventions were performed
at a referring hospital. It is certainly possible that different
types and extents of endovascular intervention could have
a variable impact on subsequent LEB. Our approach to
catheter-based interventions for CLI is admittedly conserva-
tive. We consider LEB for CLI to be a good operation and
therefore have not likely subjected our patients to highly
aggressive catheter-based procedures that could be associ-
ated with a great likelihood of impairing the performance
of subsequent LEB. Any patient who is a reasonable opera-
tive candidate with TASC type C or D disease and has vein
available for conduit is preferentially offered a bypass.
Our analysis also only considered patients who actually
underwent bypass. It is certainly possible that some patients
with a PEI and continuing or newCLIwere treatedwith pri-
mary amputation or with nonoperative therapy. What our
data show is that when a patient with a prior catheter-
based intervention undergoes lower extremity autogenous
vein reverse bypass at our institution, the result is not likely
to be any different from that in patients at our institution
who undergo LEB for CLI without PEI. Use of PEIs does
not have to impair the results of subsequent LEB for CLI.CONCLUSIONS
In a patient population treated for CLI with reversed
vein LEB, PEI was not associated with a negative impact
on mortality, patency, or limb salvage. Equivalent out-
comes for LEB performed for CLI can be achieved in
both NPEI and PEI patients. The exact circumstances un-
der which such results can be achieved is a subject for
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Submitted Oct 2, 2013; accepted Jan 9, 2014.DISCUSSIONDr Joseph L. Mills (Tucson, Ariz). The Oregon group has re-
ported today that an endovascular-ﬁrst approach has no adverse
impact on ability to perform or outcomes after open bypass if
open bypass is subsequently required. This would be comforting,
if it were true. However, these results contrast markedly with larger
published series and raise the question of whether the results you
have heard today from a single institution are generalizable. The
BASIL authors observed that patients who underwent bypass sur-
gery after an initial failed angioplasty experienced signiﬁcantly
worse amputation-free survival than did those who underwent
bypass ﬁrst as the initial therapy (P ¼ .006), suggesting that there
is a real potential adverse impact of the endovascular-ﬁrst approach
for all patients with severe limb ischemia. Others, including the
VSGNE, have made similar observations. Nolan et al reviewed
1153 patients who underwent lower extremity bypass from 2003
to 2008. Patients who had undergone a prior ipsilateral failed
percutaneous intervention had signiﬁcantly higher rates of graft
occlusion and major limb amputation at 1 year by multivariate
analysis. I will grant that vein grafts work better than prosthetic
for CLI.
Why the disparity? Almost 30% of endovascular-ﬁrst patients
reported in the Oregon series had iliac PTA, a procedure that is
quite unlikely to adversely impact LE bypass and in fact might
even be beneﬁcial (or have been planned in a staged hybrid
approach to limb salvage). What percentage of your patients had
endo by your own group (as opposed to endo performed else-
where prior to referral)?
Dr Vincent J. Santo. Twenty-one of 61 patients had their
endovascular intervention at OHSU prior to bypass. Forty patients
had their endovascular intervention prior to referral to OHSU.
DrMills.What was mean time from EVT to bypass? Delays in
achieving adequate perfusion after inadequate revascularization in
patients with wounds can lead to larger wounds and often super-
imposed infection. We know from Eurodiale and others report
that infection triples amputation risk in patients with PAD and
that persistence or nonhealing of wounds increases risk of
infection.
Dr Santo. We do not have information on the time lapse be-
tween the endovascular intervention and subsequent bypass
because for those patients treated outside the OHSU system,
this information was either imprecise or entirely unavailable.
Dr Mills. Did you speciﬁcally examine patients who had un-
dergone prior SFA stents? Ihnat et al reported that SFA stent oc-
clusion worsened SVS runoff score, leading to a net loss of onerunoff vessel per failed stent. Could you determine whether a
previous endovascular procedure impacted target site for bypass
(eg, converted fem-pop to fem-tib target)?
Dr Santo. We did not analyze the subset of patients who
received SFA stenting, as this only included eight patients and
we felt any statistical analysis would be underpowered. We also
did not attempt to analyze any changes in “best distal target” again
because the majority of patients were treated prior to arriving in
the OHSU system and we did not have baseline angiographic data.
Dr Mills. Finally, there were relatively few tibial interventions.
Were there any pedal interventions? There are reports from Italy of
adverse impact on pedal bypass after failed tibial/pedal interven-
tions. In the U.S., Vogel et al reported in 2011, using a Medicare
database of 13,258 interventions for CLI, that tibioperoneal an-
gioplasty was associated with frequent in-hospital complications,
an overall 30-day amputation rate of 23.8% for all procedures
and indications, and a 30-day rehospitalization rate of almost
30%.1 The relative aggressiveness of EVT in the Paciﬁc Northwest
seems remarkably low.
Dr Santo. There were no endovascular pedal interventions
performed in this patient population.
Dr Mills. Do you have any data on patients who underwent
amputation after failed EVT without bypass? It seems to me you
would need that data and that such patients would be systemati-
cally excluded from your series.
Dr Santo. Unfortunately, we do not have that data available
yet. We know that roughly 700 interventional and 700 diagnostic
angiograms were performed at OHSU during the same study
period, but the details of these interventions have not yet been
extracted. This is the subject of a future study and we agree, it
will be very interesting to know the outcome of these interventions
to better understand the “denominator” in this patient population.
Dr Mills. I am willing to accept that judicious EVT is unlikely
to impact ability to perform bypass. However, I also am conﬁdent
that quite a bit of injudicious infrainguinal endovascular therapy is
being widely performed, so I am not sure the results you have re-
ported today based on a single-center experience are generalizable.REFERENCE
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